The right choice of excipients can help overcome emerging challenges of manufacturing solid formulations due to limitations on active pharmaceutical ingredient (API) stability, release kinetics, bioavailability, or manufacturing costs and process efficiency of solid dose drugs – especially generics.
Solubility enhancement is a key challenge in pharmaceutical formulation development, as an increasing number of APIs in the development pipeline are reported to be poorly water-soluble. Different approaches are available to enhance the solubility of poorly water-soluble APIs. There is no one-size-fits all solution available; depending on the API and intended use, different solutions might be suitable. Hot-melt extrusion and inorganic drug carriers are among the methods applied for improving solubility in classical pharma applications.
Overcoming increasingly complex obstacles in small molecule drug manufacturing requires a strategic approach to processing, formulation, regulatory compliance, raw material quality, and supplier selection
Sterile liquid applications are often injected into the body, making it critical to minimize risk by choosing the right process to purify the API, identifying suitable excipients, defining appropriate process validation, and selecting the right filters.
Drug products must be free from bacteria and other microorganisms to ensure patient safety, requiring expert use of aseptic filtration for pharmaceutical products that cannot be terminally sterilized.
Webinar: Continuous manufacturing in solid dose - how to leverage opportunities of this new technology
Webinar: Coating with Polyvinyl Alcohol - When Coating Runs Smoothly
Webinar: Hot Melt Extrusion with PVA - A New Opportunity for Challenging APIs
Webinar: Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formulations - From Lab to Production Scale
Webinar: Total Cost of Ownership – How the Choice of Excipients Makes Your Economics
Whitepaper: API Stability in Solid Dose Formulation: Exploring the Myth of Inert Excipients
Whitepaper: New Opportunities for Oral Sustained Release Formulations with Polyvinyl Alcohol
Whitepaper: Considerations for Dosing Accuracy in a New Carrier for Dry Powder Inhalation
Inhalation drug delivery methods are attractive, noninvasive routes when rapid onset of action, minimal side effects and excellent bioavailability are desired. Accurate dosing of the dry powder inhalation (DPI) formulation can be challenging due to the small amount of dosage and fine particle size required. A combination with solid excipient carriers is often necessary to improve drug stability, dose control and prevent particle cohesion. Currently, most powder blends for DPI formulations are based on lactose monohydrate as an excipient carrier. Challenges using a lactose-based excipient include possible interaction of the lactose (being a reducing sugar) with the API, concerns for lactose intolerance in patients, and the use of an excipient of animal origin.
A new excipient based on mannitol may help to overcome some of these challenges, as it is physiologically and chemically inert with reducing sugar levels below compendial specifications. Its bulk and flow properties make it ideally suited for optimal blend homogeneity and constant dose uniformity. It also avoids the concerns over lactose intolerance and use of materials with animal origin.
Controlled-release of oral solid formulations enables better alignment of the performance of the final drug product to the therapeutic need. The benefits of sustained release include reduced dose frequency, greater patient convenience and increased compliance. In many cases, long-acting efficacy of the active pharmaceutical ingredient (API) is required. When selecting excipients for sustained-release formulations, drug manufacturers require options that deliver superior reliability and consistency.
Matrix systems are widely used because of their straight-forward and simple formulation process. In contrast to formulations with a release rate-controlling coating layer, a matrix formulation generally has a reduced risk for dose dumping and related side-effects.
A new functional excipient based on polyvinyl alcohol (PVA) with optimized particle size and properties was developed specifically for sustained release solid oral formulations. It provides consistent, sustained drug delivery over long release periods and is very well suited for direct compression processes due to very good compressibility. The fully synthetic nature allows for tight control of properties and a reliable batch-to-batch performance, thus supporting Quality by Design (QbD) approaches.
Many factors in a drug formulation can have a negative effect on the stability of the API. Reduced API stability can result in reduced shelf life, reduced efficacy, or in the worst-case scenario, cause harm to a patient.
Choosing the right excipients can help protect APIs with stability challenges due to water or heat, impact of the granulation process, or browning due to reducing sugars and peroxide impurities.
Wet granulation is the most commonly used technology for the manufacture of tablets for oral medication. However, direct compression is gaining popularity among oral solid dose manufacturers because it is a time-saving process with fewer steps. Manufacturers should consider the benefits of direct compression tableting technology for mixing ingredients in a final formulation, as well as how to optimize their formulation for good manufacturing efficiency and better yield.
Approximately 40% of marketed drugs and roughly 60% of drugs in development exhibit poor solubility, limiting their therapeutic efficacy and clinical prospects. Solubility of APIs can be improved using hot melt extrusion (HME). In this process, the API is dispersed within a matrix polymer through heating and mixing. The resulting amorphous solid dispersion – with the API incorporated in its stabilized amorphous state – exhibits enhanced API dissolution properties and apparent solubility. Manufacturers can now make use of an excipient grade of polyvinyl alcohol specifically designed for HME.
Research. Development. Production.
We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.